A scene from the first week of the second Trump administration: After the president held a White House event announcing a ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...

The measure would seem a premptive strike at a growing industry. No food engineered to include vaccines are approved for use ...

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Polk County’s level of immunization for kindergartners dropped from 96.3% in 2021 to 93.2% in 2023, still above the statewide ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Right now, we actually have no plans to move forward; it’s ready to go if we decide,” company spokeswoman said.

President Trump's $500 billion Stargate Initiative to build AI infrastructure faces blowback from his conspiracist supporters ...

New research reveals that sunburn may be caused by RNA damage, not DNA, challenging long-held beliefs about UV exposure ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...